NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: ALBERTDAVD · data 2026-10-30
Albert David Ltd
In plain words
Price: 18.1% below its 52-week high of ₹931.85.
Delivery: 62.6% of traded shares were kept for delivery over the last 10 sessions, against 66.2% over the last 60.
Latest results: a net profit of ₹32 cr for the quarter ended Jun 2026 (+303.0% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹364 cr |
| Net profit (last 12 months) | ₹23 cr |
| Sales growth, 3 years (yearly) | -0.8% |
| Profit growth, 3 years (yearly) | — |
At a glance
Promoters 62.2% (unchanged in a year), pledged 0.0%, institutions 2.2%.
P/E 19.3, dividend yield 0.7%. Price relative to earnings and book value (low is cheaper, not better).
ROE -0.4%, ROCE 0.3%, operating margin 4.7%: how much profit it earns on the money it uses.
Debt/equity 0.08, Profit growth — and sales growth -0.8% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Virtually debt-free (debt/equity 0.1 or less).
- Low return on equity (-0.4%).
- Thin operating margin (4.7%).
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q1 FY27)
ALBERTDAVD Q1 FY27 results (standalone figures, as filed on NSE).
Revenue was ₹101.34 crore, up 43.6% YoY and up 18% QoQ.
Net profit was ₹32 crore, up 303% YoY and a turn to profit from a loss last quarter.
Operating margin was 10.5% (15.1% a year ago).
EPS was ₹56.07, up 303.1% YoY and positive against a negative EPS last quarter.
ALBERTDAVD के Q1 FY27 नतीजे (स्टैंडअलोन आंकड़े, NSE पर दाखिल)।
राजस्व: ₹101.34 करोड़; पिछले साल की तुलना में 43.6% की बढ़त, पिछली तिमाही की तुलना में 18% की बढ़त।
शुद्ध मुनाफ़ा: ₹32 करोड़; पिछले साल की तुलना में 303% की बढ़त, पिछली तिमाही के घाटे से मुनाफ़े में आया।
ऑपरेटिंग मार्जिन: 10.5% (एक साल पहले 15.1%)।
EPS: ₹56.07; पिछले साल की तुलना में 303.1% की बढ़त, पिछली तिमाही के ऋणात्मक EPS से धनात्मक हुआ।
ALBERTDAVDના Q1 FY27 પરિણામો (સ્ટેન્ડઅલોન આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹101.34 કરોડ; ગયા વર્ષની સરખામણીએ 43.6% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 18% વધારો.
ચોખ્ખો નફો: ₹32 કરોડ; ગયા વર્ષની સરખામણીએ 303% વધારો, ગયા ક્વાર્ટરની ખોટમાંથી નફામાં આવી.
ઓપરેટિંગ માર્જિન: 10.5% (એક વર્ષ પહેલાં 15.1%).
EPS: ₹56.07; ગયા વર્ષની સરખામણીએ 303.1% વધારો, ગયા ક્વાર્ટરના નકારાત્મક EPSથી હકારાત્મક થઈ.
Written from the filed numbers. Not a recommendation.
Smart-money activity
19/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 14/30: Delivery 70.2% over the last 20 sessions vs 47.7% in the 40 before (1.47x); shares delivered per day 0.29x usual; 1 delivery-spike day (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results ● Dividend
- 6 Aug 26Results Q1 FY27 results: profit +303.0% YoY +18.8% next session
- 30 Jul 26Dividend Dividend ₹5 (ex-date) +0.1% next session
- 13 May 26Results Q4 FY26 results: loss widened vs a year ago -9.9% next session
- 11 Feb 26Results Q3 FY26 results: turned to profit vs a year ago +5.1% next session
- 13 Nov 25Results Q2 FY26 results: turned to loss vs a year ago -7.6% next session
- 2 Aug 25Results Q1 FY26 results: profit −57.9% YoY -4.4% next session
- 25 Jul 25Dividend Dividend ₹5 (ex-date) -2.4% next session
- 16 May 25Results Q4 FY25 results: turned to loss vs a year ago +0.1% next session
- 12 Feb 25Results Q3 FY25 results: turned to loss vs a year ago -18.3% next session
- 14 Nov 24Results Q2 FY25 results: profit −11.0% YoY -4.1% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (standalone)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹101 cr | ₹32 cr | +303.0% | 10.5% | 56.07 |
| Mar 2026 | ₹86 cr | ₹-21 cr | — | 3.2% | -37.56 |
| Dec 2025 | ₹90 cr | ₹15 cr | — | 12.0% | 26.81 |
| Sept 2025 | ₹87 cr | ₹-3 cr | -118.3% | 2.9% | -5.79 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 62.24% | 62.24% | 62.24% | 62.24% |
| Foreign institutions (FII) | 0.60% | 0.57% | 0.58% | 0.60% |
| Domestic institutions (DII) | 1.64% | 1.64% | 1.66% | 1.66% |
| Mutual funds | 0.01% | 0.01% | 0.01% | 0.01% |
| Retail investors | 25.56% | 25.31% | 25.01% | 25.32% |
| Number of shareholders | 12,709 | 13,155 | 13,555 | 13,967 |
Common questions
What was Albert David Ltd's latest quarterly profit?
Albert David Ltd reported a net profit of ₹32 cr for the quarter ended Jun 2026 (+303.0% on the same quarter a year earlier), on revenue of ₹101 cr.
How much do promoters hold in Albert David Ltd?
Promoters held 62.24% of Albert David Ltd at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Albert David Ltd debt-free?
Its latest reported debt-to-equity ratio is 0.08, which is very low.
What is Albert David Ltd's P/E ratio?
About 19.3, based on the last 12 months' earnings and a price of ₹762.8 (data 2026-10-30).
What is the 52-week high and low of Albert David Ltd?
The 52-week high is ₹931.85 and the 52-week low is ₹579.9.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Albert David Ltd | ₹762.8 | ₹437 cr | 19.3 | — | -0.4% | 0.3% | 0.08 | -11.0% |
| Praveg Limited | ₹204.91 | ₹539 cr | — | — | -2.5% | 1.6% | 0.38 | -24.4% |
| Infinium Pharmachem Ltd. | ₹281 | ₹438 cr | 36 | 3.6 | 10.5% | 13.5% | 0.19 | +8.0% |
| Jenburkt Pharmaceuticals Ltd | ₹853.6 | ₹377 cr | 11.5 | — | 18.8% | 22.7% | 0.01 | -18.1% |
| Medicamen Biotech Limited | ₹256.2 | ₹347 cr | 31.3 | — | 3.9% | 5.5% | 0.18 | -27.6% |
| Aarey Drugs & Pharmaceuticals Ltd. | ₹106.26 | ₹298 cr | 72.4 | — | 2.7% | 6% | 0.33 | +15.4% |
Compare ALBERTDAVD with PRAVEG in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open ALBERTDAVD in NSE Scanner →